Arimoclomol for NPC receives Rare Pediatric Disease Designation
19 janv. 2018 02h16 HE
|
ORPHAZYME A/S
Company announcementOrphazyme A/SNo. 01/2018 ...
Major shareholder announcement
18 déc. 2017 07h08 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 17/2017 ...
Orphazyme assumes sponsorship of Phase II/III sIBM trial
15 déc. 2017 09h20 HE
|
ORPHAZYME A/S
Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...
Stabilisation measures taken and end of stabilisation period
14 déc. 2017 13h02 HE
|
ORPHAZYME A/S
Company announcementNo. 16/2017 NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN This announcement...
Orphazyme publishes offering circular and the indicative offer price range for its IPO
06 nov. 2017 03h09 HE
|
Orphazyme A/S
Company announcement
Orphazyme A/S
No. 2/2017
Ole Maaløes Vej 3
DK-2200 Copenhagen N
www.orphazyme.com
Company Registration No....